googletag.defineOutOfPageSlot('/23357399017/Offerwall-Ad-Unit-4ac7776188ac0199', 'div-gpt-ad-offerwall').addService(googletag.pubads());
DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Category Reports Biotech

Tickers reports and analysis

ATYR Atyr Pharma Inc

aTyr Pharma ($ATYR) is a clinical-stage biotech developing first-in-class therapies from its tRNA synthetase platform, targeting fibrotic and inflammatory lung diseases. The company's lead asset, efzofitimod (a selective NRP2 modulator), suffered a major setback with the Phase 3 EFZO-FIT trial miss in pulmonary sarcoidosis (announced Sept 15, 2025), causing an ~80% stock drop from ~$4-5 to sub-$1 levels.

VNDA Vanda Pharmaceuticals Inc

Vanda is not a pre-revenue biotech: it is a commercial-stage CNS company with three marketed products (Fanapt, Hetlioz, Ponvory) and two late stage assets that matter for the next 12–24 months: Nereus (tradipitant) for motion sickness, now approved, and Bysanti (milsaperidone) with a PDUFA target action date on 21 February 2026 for schizophrenia and bipolar I disorder.

VRDN Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) has started 2026 by reaffirming its "transformational" year narrative in the January 6 PR, which serves as a comprehensive roadmap update without any timeline shifts or negative surprises. This builds directly on the December 22, 2025 BLA acceptance for veligrotug (VRDN-001) in TED with Priority Review and PDUFA target of June 30, 2026 (as detailed in the previous report).

RGNX Regenxbio

RGX-121 puts Regenxbio at the threshold of its first potential standalone approval, while the retina (AbbVie) and Duchenne programs build a second and third pillar for 2026–2027. The equity story is a classic “platform + royalty + binary PDUFA” mix, with a balance sheet extended into early 2027 via upfronts and royalty monetization.

CVKD Cadrenal Therapeutics Inc

cvld

Cadrenal Therapeutics (NASDAQ: CVKD) is a clinical-stage biopharma headquartered in Ponte Vedra, Florida, focused on anticoagulation solutions for high-risk patients who are poorly served by current therapies. The company was formed in 2022 around tecarfarin and, through two 2025 acquisitions, has expanded into a broader platform combining VKA, Factor XIa and 12-LOX mechanisms.

Weekly Briefing – Fed, Geopolitics, GLP-1 Obesity & Small Caps

weeka2

Going into the 27–28 January FOMC, the message is basically “don’t expect fireworks”: after the 2025 cuts, the Fed keeps describing policy as “well positioned”, with inflation gliding down towards (but not yet at) target and real growth still positive. Futures now see a very high probability of a clean hold next week and push the bulk of any extra easing into late 2026.

ETON  Pharmaceuticals Inc

After years of being “just a pipeline story”, Eton has transitioned into a small but diversified rare-disease platform with multiple approved assets and a focused late-stage pipeline anchored by ET-400 and ET-600.

AQST & PHAR -Countdown Jan 31 PDUFA

We are on Friday, January 23, 2026 (Italy time). For January, in your catalyst tracker there are essentially two PDUFAs still “missing” that matter for this piece: Aquestive (AQST) with Anaphylm and Pharming (PHAR) with the pediatric Joenja sNDA (4–11 years, APDS). Both currently carry a PDUFA target action date of January 31, 2026.

KPTI Karyopharm Therapeutics

At the dawn of 2026, Karyopharm Therapeutics stands at a critical inflection point that will determine not only near-term share performance, but in many respects the long-term viability of the company. After spending the last five years building a commercial foothold in late-line relapsed/refractory multiple myeloma, Karyopharm has repositioned the selinexor franchise toward two potentially transformative Phase 3 readouts: the SENTRY trial in myelofibrosis and the XPORT-EC-042 trial in endometrial cancer maintenance.

IONS Ionis Pharmaceuticals

Ionis is one of the long-standing pioneers of antisense oligonucleotide (ASO) therapeutics. Founded in 1989, the company has taken antisense from a controversial idea to an approved therapeutic class with multiple marketed products and a deep late-stage pipeline.

HELP Helus Pharma Inc

Helus Pharma is the new brand for Cybin, now trading under the ticker HELP on the Nasdaq Global Market and on Cboe Canada. The company is trying to position itself as a “psychedelic 2.0” / mental-health pure play, built around proprietary novel serotonergic agonists (NSAs) rather than classic psychedelic molecules

BMEA Biomea Fusion Inc

bmea2

Biomea Fusion has quietly morphed from an oncology story into a pure diabetes and obesity medicines company, with a potentially first-in-class oral menin inhibitor (icovamenib) for insulin-deficient type 2 diabetes and an oral GLP-1 receptor agonist (BMF-650) aimed at obesity. 2026 is all about execution: Phase II programs in T2D, first human weight-loss data for BMF-650 and a cash runway that, after the 2025 down-rounds and cost cuts, now stretches into 2027.

FULC Fulcrum Therapeutics Inc

This note is a follow-up to the previous Merlintrader deep dive on Fulcrum Therapeutics (link to the earlier report). Since then, Fulcrum has reshaped its story around pociredir, an oral HbF inducer for sickle cell disease (SCD), delivered a series of positive PIONEER data updates and, crucially, raised fresh capital to extend runway well beyond the next set of readouts.

ALT Altimmune Inc

As of the afternoon session on 21 January 2026, Altimmune is trading around 4.5–4.6 USD, up roughly 9% versus the prior close. Volumes are clearly above a quiet day but not at “capitulation” or “meme-stock” levels. There is no new 8-K or press release dated today, and the official IR feed has not dropped fresh clinical or corporate news.

NVAX Novavax and Pfizer

The short version: Novavax is no longer just fighting for survival as a COVID single-product story. With Sanofi first and Pfizer now, Matrix-M is slowly turning into a royalty platform. The balance sheet is still tight and the story remains binary, but the “all-or-nothing” risk has shifted a bit more towards “long-duration option on partner execution”.